European Commission Approves Bristol-Myers Squibb’s Opdivo (nivolumab) for the Adjuvant Treatment of Adult Patients with Melanoma with Involvement of Lymph Nodes or Metastatic Disease Who Have Under
Go back to European Commission Approves Bristol-Myers Squibb’s Opdivo (nivolumab) for the Adjuvant Treatment of Adult Patients with Melanoma with Involvement of Lymph Nodes or Metastatic Disease Who Have Under| Bristol-Myers Squibb (NYSE: BMY) | Delayed: 58.13 +2.32 (4.16%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $55.81 | 52 Week High | $77.12 | |||
| Open | $56.65 | 52 Week Low | $49.03 | |||
| Day High | $58.14 | P/E | 37.75 | |||
| Day Low | $56.41 | EPS | $1.54 | |||
| Volume | 10,003,974 | |||||
